Sotera Health Company SHC
18.34
(0.11)
(0.60%)
as of 25 Sep
- Market cap
- $5.3B
- P/E
- 32.1×
Follow SHC
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
31.14 | 34.98 | 65.33 | 82.79 |
+8 more quarters Free account |
P/S ratio |
4.17 | 3.44 | 4.30 | 3.88 | |
P/FCF ratio |
45.01 | 42.18 | 33.58 | 51.59 | |
P/Operating CF |
57.32 | 138.79 | 48.58 | 62.80 | |
P/B ratio |
7.62 | 6.56 | 8.27 | 8.12 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.71 | 5.05 | 5.93 | 5.57 | |
EV/EBITDA |
13.10 | 11.69 | 13.68 | 12.98 | |
EV/Operating CF |
23.78 | 22.98 | 24.02 | 26.71 | |
EV/FCF |
61.64 | 61.96 | 46.23 | 73.94 | |
Quick Ratio |
2.23 | 2.21 | 1.98 | 1.88 | |
Current Ratio |
2.80 | 2.82 | 2.46 | 2.38 | |
Net Debt/EBITDA |
13.22 | 17.72 | 13.55 | 13.75 | |
Debt/Assets |
67.47% | 68.96% | 68.48% | 70.22% | |
Debt/Equity |
3.35 | 3.58 | 3.69 | 4.06 | |
Asset Turnover |
0.37 | 0.38 | 0.37 | 0.36 | |
Operating CF/Net income |
1.65 | 1.11 | 2.96 | 1.47 | |
Capex/Depreciation |
(1.33) | (1.43) | (1.49) | (1.22) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
21.21% | 24.36% | 18.95% | 20.33% | |
Intangible Assets out of Total Assets |
0.41 | 0.43 | 0.43 | 0.44 | |
Share Based Compensation of Revenue |
2.25% | 5.14% | 2.49% | 2.55% | |
Graham Net Nets |
(0.39) | (0.50) | (0.41) | (0.46) | |
Graham Number |
5.47 | 4.49 | 3.60 | 2.88 | |
Earnings Yield |
3.21% | 2.86% | 1.53% | 1.21% | |
Free Cash Flow Yield |
2.22% | 2.37% | 2.98% | 1.94% | |
Revenue per Share |
1.12 | 0.98 | 1.07 | 1.10 | |
Operating CF per Share |
0.31 | 0.10 | 0.36 | 0.25 | |
Capex per Share |
(0.16) | (0.16) | (0.18) | (0.13) | |
Free Cash Flow per Share |
0.15 | (0.06) | 0.18 | 0.12 | |
Cash per Share |
1.25 | 1.11 | 1.22 | 1.06 | |
Shareholders Equity per Share |
2.33 | 2.19 | 2.13 | 1.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.33 | 2.19 | 2.13 | 1.94 | |
Free Cash Flow |
42.05 | (16.73) | 52.41 | 34.98 | |
Working Capital |
415.22 | 378.17 | 363.83 | 335.42 | |
Capital Expenditures |
(46.45) | (46.17) | (50.70) | (36.17) | |
Net Current Asset Value |
(1,994.68) | (2,027.42) | (2,043.74) | (2,057.88) | |
EV/EBIT |
17.40 | 15.76 | 19.05 | 18.63 | |
Capex to Sales |
0.14 | 0.16 | 0.17 | 0.12 | |
Net Profit Margin |
16.69% | 9.49% | 11.48% | 15.55% | |
Price to Operating Income |
12.71 | 10.73 | 13.84 | 13.00 | |
| Other line items | |||||
Average Receivables |
153.28 | 138.38 | 147.16 | 149.32 | |
Average Payables |
82.34 | 73.40 | 66.53 | 66.07 | |
Average Inventory |
58.16 | 59.27 | 51.77 | 51.76 | |
Average Assets |
3,261.76 | 3,166.71 | 3,167.42 | 3,167.45 | |
Average Common Equity |
588.47 | 518.30 | 505.47 | 510.32 |
Columns are period end dates